Liver steatosis in children with chronic hepatitis C

American Journal of Gastroenterology

Volumn 101, Issue 11, 2006, Pages 2611-2615

  Guido, Maria ^a,e   Bortolotti, Flavia ^a   Jara, Paloma ^b   Giacomelli, Luciano ^a   Fassan, Matteo ^a   Hierro, Loreto ^b   Nebbia, Gabriella ^c   Zancan, Lucia ^a   Rugge, Massimo ^a,d  

^a UNIVERSITY OF PADOVA   (Italy)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c UNIVERSITY OF MILAN   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e Istituto di Anatomia Patologica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ARTICLE; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; DISABILITY SEVERITY; DISEASE ASSOCIATION; ETHNOLOGY; FATTY LIVER; FEMALE; FIBROSIS; HEPATITIS C; HISTOLOGY; HUMAN; LIVER BIOPSY; LIVER CELL; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; BIOPSY; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; PREVALENCE; TRIGLYCERIDES;

EID: 33750510293     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00918.x     Document Type: Article

References (42)

1. Seef LB. Natural history of chronic hepatitis C. Hepatology 2002;36:S35-46.
2. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
3. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-9.
4. Ryder SD, Irving WL, Jones DA, et al. Trent Hepatitis C Study Group. Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study. Gut 2004;53:451-5.
5. Scheuer PJ, Ashrafzadeh P, Sherlok S, et al. The pathology of hepatitis C. Hepatology 1992;15:567-71.
6. Czaja AJ, Carpenter HA, Santrach PJ, et al. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998;29:198-206.
7. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-15.
8. Monto A, Alonzo J, Watson JJ, et al. Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002;36:729-36.
9. Hwang SJ, Luo JC, Chu CW, et al. Hepatic steatosis in chronic hepatitis C virus infection: Prevalence and clinical correlation. J Gastroenterol Hepatol 2001;16:190-5.
10. Adinolfi LE, Utili R, Andreana A, et al. Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci 2001;46:1677-83.
11. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
12. Westin J, Nordlinder H, Lagging M, et al. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002;37:837-42.
13. Negro F. Hepatitis C virus and liver steatosis: When fat is not beautiful. J Hepatol 2004;40:533-5.
14. Guido M, Rugge M, Jara P, et al. Chronic hepatitis C in children: The pathological and clinical spectrum. Gastroenterology 1998;115:1525-9.
15. Jara P, Resti M, Hierro L, et al. Chronic hepatitis C virus infection in childhood: Clinical patterns and evolution in 224 white children. Clin Infect Dis 2003;36:275-80.
16. Guido M, Bortolotti F, Leandro G, et al. Fibrosis in chronic hepatitis C acquired in infancy: Is it only a matter of time? Am J Gastroenterol 2003;98:660-3.
17. Bortolotti F, Muratori L, Jara P, et al. Hepatitis C virus infection associated with liver-kidney microsomal antibody type 1 (LKM1) autoantibodies in children. J Pediatr 2003;142:185-90.
18. Birnbaum AH, Shneider BL, Moy L. Hepatitis C in children. N Engl J Med 2000;342:290-1.
19. Cole TJ, Faith MS, Pietrobelli A, et al. What is the best measure of adiposity change in growing children: BMI, BMI %, BMI z-score or BMI centile? Eur J Clin Nutr 2005;59:419-25.
20. Tisminetzky S, Gerotto M, Pontisso P, et al. Comparison of genotyping and serotyping methods for the identification of hepatitis C virus types. J Virol Methods 1995;55:303-7.
21. Guido M, Rugge M. Liver biopsy sampling in chronic viral hepatitis. Semin Liver Dis 2004;24:89-97.
22. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
23. Hezode C, Roudot-Thoraval F, Zafrani ES, et al. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat 2004;11:455-8.
24. Rubbia-Brandt L, Leandro G, Spahr L, et al. Liver steatosis in chronic hepatitis C: A morphological sign suggesting infection with HCV genotype 3. Histopathology 2003;39:119-24.
25. Fujie H, Yotsuyanagi H, Moriya K, et al. Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J Med Virol 1999;59:141-5.
26. Kumar D, Farrell GC, Fung C, et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002;36:1266-72.
27. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peg-interferon or interferon alpha-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
28. Sanyal AJ, Contos MJ, Sterling RK, et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 2003;98:2064-71.
29. Lavine JE, Schwimmer JB. Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis 2004;8:549-58.
30. Ong JP, Younossi ZM, Speer C, et al. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001;2:266-71.
31. Brunt EM, Ramrakhiani S, Cordes BG, et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003;16:49-56.
32. Ramesh S, Sanyal AJ. Hepatitis C and non-alcoholic fatty liver disease. Semin Liver Dis 2005;4:399-413.
33. Roberts EA. Nonalcoholic steatohepatitis in children. Curr Gastroenterol Rep 2003;5:253-9.
34. Suriawinata A, Fiel MI. Liver pathology in obesity. Semin Liver Dis 2005;4:363-70.
35. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005;42:641-9.
36. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004;40:484-90.
37. Fartoux L, Chazouilleres O, Wendum D, et al. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005;41:82-7.
38. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-9.
39. Bressler BL, Guindi M, Tomlinson G, et al. High body mass index is an independent risk factor for non-response to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-44.
40. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94.
41. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413-9.
42. Roberts EA. Non-alcoholic fatty liver disease (NAFLD) in children. Front Biosci 2005;10:2306-18.